Boston Scientific patent loses UK portion
The Court of Appeal in the U.K. has upheld a decision to revoke the U.K. portion of a European Patent belonging to Angiotech Pharmaceuticals Inc., which is exclusively licensed to Natick-based Boston Scientific Corp. for use in the field of coronary stents.
In February of last year, Conor Medsystems began proceedings against Angiotech and the University of British Columbia, requesting that the High Court of Justice in the U.K. invalidate the patent due to all claims of the patent lacking novelty or are obvious in light of the state of scientific knowledge at the priority date of the patent. The court agreed, declaring it invalid on February 24, 2006. Angiotech would later appeal the decision, which today was dismissed.
The European patent remains valid and enforceable in all other designated European
jurisdictions. The European patent is part of a worldwide patent portfolio exclusively licensed to Boston Scientific.
"While we are disappointed with the Court's decision, we are confident in the strength and validity of Angiotech's patent portfolio elsewhere around the world," said Boston Scientific spokesman Paul Donovan.
WBJ Web Partners
Most Recent
Most Recent
0 Comments